Scleroderma is now part of a federal program that aims to help understand underlying mechanisms and develop new treatments and diagnostic targets for autoimmune conditions. The Foundation for the National Institutes of Health (FNIH) has expanded its Accelerating Medicines Partnership Autoimmune and Immune-Mediated Diseases (AMP AIM) program,…
News
An investigational off-the-shelf, or readily available, CAR T-cell therapy has shown early signs of effectiveness — with clinical improvements and no serious safety concerns — in the first four people with systemic sclerosis (SSc) treated in an ongoing clinical trial in the U.S. and Europe. That’s according to preliminary…
A clinical trial will study investigational therapies in people at the earliest stages of systemic sclerosis (SSc), before irreversible organ damage has occurred. Contract research organization Indero and the World Scleroderma Foundation (WSF) are partnering on the trial, called WSF SHIELD. It will test multiple investigational therapies in…
Off-label treatment with JAK inhibitors appeared to keep lung function stable and reduce skin thickening, joint pain, and swelling in a small real-world study of systemic sclerosis (SSc). They also caused some side effects and their use needs further confirmation in larger controlled studies, researchers wrote. The study, “…
People with scleroderma who are triple autoantibody-negative — meaning they don’t have three common disease-associated antibodies — are more likely to experience muscle damage and lung disease than others with the rare condition, a new study shows. Conversely, data indicate that patients negative for the three antibodies are less…
A new nanoparticle-based delivery of kaempferol, a compound found in plants, vegetables, and herbs, reduced skin thickening, inflammation, and levels of molecules that induce fibrosis (scarring) in a mouse model of systemic sclerosis (SSc), according to a study. Designed for delivery through the skin, the KLE treatment strategy combines…
A specialized MRI technique may help detect early lung abnormalities in people with systemic sclerosis (SSc), even when standard tests show only mild lung disease, a new U.S. study suggests. Using Xenon MRI, or Xe-MRI, which tracks how gases move through the lungs, researchers found that women with SSc showed…
June is Scleroderma Awareness Month, culminating on the 29th with World Scleroderma Day, and is a time, advocates say, to educate others about the autoimmune disease and “find optimism in the latest research that promises better tomorrows.” That’s the message from the National Scleroderma Foundation as the nonprofit announces…
The loss of capillaries in the hands may directly contribute to local bone loss in people with systemic sclerosis (SSc), a study revealed for the first time. Data showed that SSc patients with fewer capillaries at the base of the fingernails had lower bone density in the hands. Such…
BLR-200, a new therapy for scleroderma that’s being developed by a biotech startup in Chicago, may prevent activation of a group of cells involved in the disease’s characteristic scarring — possibly preventing patches of hardened skin from forming. That’s according to new research conducted by the startup,…
Recent Posts
- Routine blood test may help flag lung disease risk in diffuse SSc, study says
- Nearly half with SSc consider facial cosmetic therapy, survey finds
- Inhaled therapy for Raynaud’s attacks put on FDA fast track
- Vitamin B3 may improve blood vessels in scleroderma-related Raynaud’s
- John Stamos to be honored for longtime support of scleroderma research
- Study maps shift in prescribing patterns as guidelines evolve
- Blood protein may help predict lung decline in scleroderma-related ILD
- Lack of small blood vessel damage patterns may predict milder SSc
- Wireless sensor may help track scleroderma skin changes at home
- New scleroderma survey seeks patient input to guide future research